Biocytogen Earns Full AAALAC Accreditation, Reinforcing Excellence in Translational Research and Drug Discovery
15.6.2026 14:00:00 CEST | Business Wire | Press release
Biocytogen today announced that its Boston research facility has been awarded Full Accreditation by AAALAC International, a globally recognized organization dedicated to promoting excellence in laboratory animal care and use.
The accreditation reflects Biocytogen’s continued commitment to maintaining the highest standards of animal welfare, scientific integrity, and operational excellence across its preclinical research and drug discovery activities.
Biocytogen’s Boston facility serves as a key hub supporting the company’s expanding portfolio of drug discovery and translational research capabilities. The facility enables a broad range of in vivo studies supporting antibody therapeutics, multispecific antibodies, ADCs, cell therapies, and other innovative biologics programs for pharmaceutical and biotechnology partners worldwide.
Through its proprietary BioMice™ platform, Biocytogen has established one of the industry’s most comprehensive collections of genetically engineered disease models spanning oncology, immunology and autoimmune diseases, metabolic disorders, neuroscience, ophthalmology, and other therapeutic areas. Combined with the company’s RenMice® fully human antibody discovery platforms and AI-enabled antibody discovery technologies, these capabilities help global partners accelerate target validation, therapeutic discovery, and preclinical development.
“Receiving full AAALAC accreditation represents an important milestone for our Boston research operations and further demonstrates our commitment to scientific excellence, animal welfare, and responsible research practices,” said Madeline Lee, Chief Operating Officer of Biocytogen. “As we continue expanding our global partnerships, this accreditation provides additional assurance that our research programs are conducted under the highest standards of animal care, quality, and scientific rigor. Together with our industry-leading disease model portfolio and antibody discovery platforms, we remain committed to helping our partners accelerate the development of innovative medicines for patients worldwide.”
AAALAC International accreditation is widely regarded as the gold standard for laboratory animal care and use programs worldwide. The accreditation recognizes institutions that voluntarily demonstrate excellence beyond regulatory requirements and maintain a culture of continuous improvement in animal welfare, ethical research practices, and scientific quality.
This achievement further strengthens Biocytogen’s ability to support global pharmaceutical and biotechnology companies with high-quality translational research, in vivo pharmacology, and therapeutic discovery solutions. By upholding the highest standards of animal welfare and scientific rigor, Biocytogen helps partners generate reliable preclinical data, reduce development risk, and accelerate the advancement of next-generation medicines across oncology, immunology, metabolic diseases, neuroscience, ophthalmology, and other therapeutic areas.
About Biocytogen
Biocytogen (SSE: 688796; HKEX: 02315) is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Founded on gene editing technology, Biocytogen has established a dual-engine platform combining a fully human antibody library with an extensive target-humanized mouse model portfolio, enabling a systematic approach to accelerating global drug discovery and development.
Biocytogen has independently developed its proprietary RenMice® (RenMab®/RenLite®/RenNano®/RenTCR™/RenTCR mimic™) platforms for fully human monoclonal/bispecific/multispecific antibody discovery, bispecific antibody-drug conjugate discovery, hu-VHH discovery, and TCR mimic antibody discovery, and has established a sub-brand, RenSuper™ Biologics, to explore global partnerships for an off-the-shelf library of >1,000,000 fully human antibody sequences against over 1000 targets for worldwide collaboration. As of December 31, 2025, more than 350 agreements for therapeutic antibodies and clinical assets—spanning co-development, out-licensing, and transfers—have been established globally, including landmark partnerships with leading multinational pharmaceutical companies (MNCs). Biocytogen pioneered the generation of drug target knock-in humanized models for preclinical research, and currently provides a few thousand off-the-shelf animal and cell models under the company's sub-brand, BioMice™, along with preclinical pharmacology and gene-editing services for clients worldwide. Headquartered in Beijing, Biocytogen has branches in China (Haimen, Jiangsu, Shanghai), the USA (Boston, San Francisco, San Diego), and Germany (Heidelberg). For more information, please visit https://biocytogen.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260615951394/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Elite Tech, Accessible Price - Introducing the Logitech G3 Series Mouse and Keyboard for PC Gaming16.6.2026 09:05:00 CEST | Press release
Elite Precision - Unleash pro-grade speed with the G305 X SUPERLIGHT gaming mouse and G316 X 98 gaming keyboard. Featuring the HERO 44K sensor and an 8 kHz report rate, this duo delivers sub-micron accuracy and near-instant response for every player.Boutique Customization - Get that premium "thock" without the DIY hassle. The G316 X 98 features a snap-fit gasket design, hot-swappable switches, and an interactive dot-matrix display for a truly custom feel.The Power Ecosystem - High performance, accessible price. Elevate your setup with the G305 X SUPERLIGHT mouse, G316 X 98 mechanical keyboard, and the plush G325 wireless headset—the ultimate gear for total immersion. Logitech G today announced the expansion of the G3 Series suite of PC Gaming products. Designed to bring pro-inspired performance to more gamers, the extended lineup features the G305 X SUPERLIGHT wireless gaming mouse and the G316 X 98 wired mechanical gaming keyboard. This press release features multimedia. View the full
Ny analyse: AI udfordrer SMV’ers digitale konkurrenceevne16.6.2026 09:01:00 CEST | Pressemeddelelse
AI skaber nye konkurrencevilkår og udfordringer for virksomheder digitalt, og særligt SMV’er har svært ved at følge med udviklingen. Det viser en ny undersøgelse blandt over 10.000 europæiske virksomheder, hvoraf 556 af dem er danske. Virksomheder har aldrig haft adgang til så mange digitale kanaler, men med udviklingen af AI, øget konkurrence og skiftende algoritmer er det digitale landskab blevet mere komplekst end nogensinde før, og vilkårene ændrer sig lige nu hurtigere, end mange kan nå at følge med. En ny omfattende erhvervsundersøgelse fra hosting-virksomheden team.blue, som i Danmark har 220 medarbejdere og 250.000 kunder med kontorer i Skanderborg og København, viser, at det er blevet sværere for virksomheder, særligt SMV’er, at styre deres digitale forretningsvækst. Ifølge undersøgelsen, State of European Business Report 2026, som er foretaget blandt mere end 10.000 virksomheder på tværs af 32 lande, herunder 556 fra Danmark, hvoraf størstedelen er SMV’er, er der opstået et s
Tampere Philharmonic Orchestra Appoints Kristian Sallinen as the Next Chief Conductor16.6.2026 09:00:00 CEST | Press release
Kristian Sallinen has been appointed Chief Conductor and Artistic Director of the Tampere Philharmonic Orchestra. He will begin his three-year term in August 2027, following the tenure of British conductor Matthew Halls. Sallinen will conduct a minimum of 7–8 programmes each season alongside other projects and will become the thirteenth Chief Conductor in the Finnish orchestra’s 96-year history. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260615800659/en/ Conductor Kristian Sallinen will begin his tenure as the new Chief Conductor of the Tampere Philharmonic Orchestra in August 2027. Photo: Antti Rintala. Sallinen last appeared in Tampere in September 2025, conducting Richard Strauss’s Der Rosenkavalier Suite and Magnus Lindberg’s Concerto for Orchestra. He will return this September to lead a programme of Finnish music by Jean Sibelius, Kaija Saariaho and Väinö Raitio. – I am deeply honoured and grateful for the trust th
ABB Robotics and PSYONIC Use Human-Generated Data to Advance Robotic Dexterity16.6.2026 06:01:00 CEST | Press release
ABB Robotics and PSYONIC collaborate to revolutionize grasping and dexterity, a core capability for Autonomous Versatile Robotics™ ABB GoFa™ helps test PSYONIC’s Ability Hand for robotics, combining touch sensing, compliant design and human-derived training data Dexterity remains a major challenge for industry; improved handling can reduce engineering time by up to 30%¹ ABB Robotics is collaborating with California bionics company, PSYONIC, to advance robotic gripping and dexterity using a new approach that utilizes real-world manipulation data from human prosthetic use. By combining the PSYONIC Ability Hand with an ABB GoFa™ cobot, the collaboration will explore how touch and motion data generated by human prosthetic use can be used to train robots to perform delicate, variable tasks that have traditionally been difficult to automate. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612749544/en/ “Human dexterity and the i
Signaloid Announces Availability of Amazon AWS Machine Image (AMI) for Accelerating Compute Workloads Ranging from Finance to Reinforcement Learning16.6.2026 06:00:00 CEST | Press release
British computing technology company Signaloid today announced the release of the Signaloid Compute Engine Amazon Machine Image (AMI) via AWS Marketplace. The release enables organizations to deploy Signaloid’s distribution-extended compute hardware (UxHw®) technology within their Amazon Virtual Private Clouds (VPCs). The AMI provides access to UxHw, which delivers orders-of-magnitude performance improvements on x86_64 and ARM (AArch64) AWS Elastic Compute Cloud (EC2) instances. Without requiring software rewrites, UxHw enables existing applications to compute directly on probability distributions, automating algorithms such as Monte Carlo methods in finance and physics, importance sampling in reinforcement learning, and particle filters in physical AI and robotics. The technology works through binary translation and optimization at the LLVM intermediate representation (LLVM IR) level, with optional hardware acceleration via FPGAs and Signaloid’s C0-ASIC that was recently taped-out in
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom